William Blair reiterated their buy rating on shares of Nektar Therapeutics (NASDAQ:NKTR) in a report published on Friday morning, AnalystRatings.com reports.
“We traveled with LeMaitre management last week as the company met with Barrington clients in Richmond, VA. This marked the second time in a month that we have spent time on the road with members of this management team and the messaging remains consistent and long-term bullish despite some short-term challenges.”,” the firm’s analyst wrote.
Several other brokerages have also commented on NKTR. HC Wainwright restated a hold rating and set a $47.00 price target on shares of Nektar Therapeutics in a research note on Tuesday, February 19th. Mizuho restated a buy rating on shares of Nektar Therapeutics in a research note on Tuesday, February 19th. BMO Capital Markets initiated coverage on Nektar Therapeutics in a research note on Friday, February 22nd. They set an outperform rating and a $75.00 price target on the stock. ValuEngine downgraded Nektar Therapeutics from a sell rating to a strong sell rating in a research report on Friday, February 22nd. Finally, Piper Jaffray Companies set a $100.00 price objective on Nektar Therapeutics and gave the company a buy rating in a research report on Friday, March 1st. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the stock. Nektar Therapeutics currently has an average rating of Buy and a consensus target price of $68.50.
Shares of Nektar Therapeutics stock opened at $33.40 on Friday. The firm has a market cap of $5.93 billion, a PE ratio of 8.84 and a beta of 2.82. The company has a debt-to-equity ratio of 0.21, a quick ratio of 14.83 and a current ratio of 14.94. Nektar Therapeutics has a 12 month low of $29.22 and a 12 month high of $69.76.
Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.03. The firm had revenue of $28.22 million for the quarter, compared to analyst estimates of $25.45 million. Nektar Therapeutics had a return on equity of 37.63% and a net margin of 55.65%. During the same quarter last year, the firm posted ($0.60) earnings per share. Sell-side analysts predict that Nektar Therapeutics will post -3.14 earnings per share for the current year.
In related news, CAO Jillian B. Thomsen sold 1,928 shares of the firm’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $31.37, for a total transaction of $60,481.36. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Stephen K. Doberstein sold 3,461 shares of the firm’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $31.37, for a total value of $108,571.57. Following the sale, the senior vice president now directly owns 95,913 shares in the company, valued at approximately $3,008,790.81. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 159,949 shares of company stock worth $5,232,600. 4.31% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC boosted its holdings in Nektar Therapeutics by 8.5% in the fourth quarter. FMR LLC now owns 25,961,520 shares of the biopharmaceutical company’s stock worth $853,355,000 after acquiring an additional 2,041,954 shares in the last quarter. Vanguard Group Inc boosted its holdings in Nektar Therapeutics by 3.6% in the third quarter. Vanguard Group Inc now owns 18,922,650 shares of the biopharmaceutical company’s stock worth $1,153,525,000 after acquiring an additional 660,907 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Nektar Therapeutics by 20.7% in the first quarter. Wellington Management Group LLP now owns 12,961,558 shares of the biopharmaceutical company’s stock worth $435,507,000 after acquiring an additional 2,220,193 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Nektar Therapeutics by 7.3% in the first quarter. Geode Capital Management LLC now owns 2,398,081 shares of the biopharmaceutical company’s stock worth $80,433,000 after acquiring an additional 163,885 shares in the last quarter. Finally, First Trust Advisors LP boosted its holdings in Nektar Therapeutics by 11.6% in the fourth quarter. First Trust Advisors LP now owns 2,309,172 shares of the biopharmaceutical company’s stock worth $75,902,000 after acquiring an additional 240,272 shares in the last quarter. 92.28% of the stock is owned by institutional investors and hedge funds.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Recommended Story: Does a trade war provide a risk to the global economy?
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.